U.S. Stock Market Midday Update

Instinct Bio fell 57.89%. Based on recent key news:

1. On July 28, Instinct Bio secured $150 million in equity financing to advance its regenerative medicine platform and strategic growth. This move aims to enhance the company's technological capabilities and market competitiveness, but the market remains skeptical about its future profitability, leading to a significant drop in stock price.

2. On July 28, the company issued a statement emphasizing that its forward-looking statements should not be overly relied upon and made no commitment to update these statements. Investors are concerned about the uncertainty surrounding the company's future performance, exacerbating stock price volatility. Competition in the regenerative medicine field is intensifying, increasing risks.

Stocks with High Trading Volume in the Industry

Forte Biosciences fell 0.09%. Based on recent key news:

1. On July 27, Forte Biosciences agreed to be acquired by the Belgium-Netherlands immunology company argenx for approximately $2.2 billion. Argenx will acquire Forte Biosciences for $77 per share in cash, a premium of about 41% over last Friday's closing price. This news drove Forte Biosciences' stock price up 39% in pre-market trading.

2. On July 27, Forte Biosciences' main project FB102 showed early potential for treating vitiligo and celiac disease. The clinical trial results for this project were positive, with Phase II results expected to be announced in the second half of this year, further boosting market confidence in the company.

3. On July 27, Evercore ISI analysts downgraded Forte Biosciences' rating to Hold, with a target price equal to the acquisition price. Despite the downgrade, the acquisition news still had a positive impact on the stock price. The immunology sector has performed strongly recently, with significant capital inflows.

AbbVie rose 0.90%. Based on recent news:

1. On July 29, AbbVie's continued investment and innovation in the immunology field drove its stock price up. AbbVie has treated over 1 million patients globally and received approvals for 19 immunology-mediated diseases, demonstrating strong market performance.

2. On July 28, analysts expressed concerns about AbbVie's accelerating decline in Humira revenue, but strong sales of Skyrizi and Rinvoq offset this impact. The combined revenue of these two drugs reached $6.6 billion last quarter, driving a 16.4% increase in immunology revenue.

3. On July 27, increased market focus on the Federal Reserve's interest rate decision and economic data heightened short-term volatility. Policy signals, technology company performance, and inflation data may influence market expectations and valuations. Increased market focus on the Federal Reserve's interest rate decision and economic data heightened short-term volatility.

Amgen rose 0.74%, with increased trading volume. Based on recent key news:

1. On July 29, Amgen announced that it will release its second-quarter financial report on August 4, and the market is full of expectations for its performance, driving the stock price up. Source: Amgen official website

2. On July 29, the EMA supported Amgen's Repatha to expand label use in the EU to reduce cardiovascular risk, enhancing market confidence. Source: Public Technologies

3. On July 29, the results of Amgen's bone density trials raised safety concerns, leading to a brief fluctuation in stock price. Source: TipRanks The healthcare industry faces regulatory risks, with significant capital inflows.

Stocks ranked among the top in industry market capitalization

Gilead Sciences fell 0.14%. Based on recent news,

1. On July 28, GlaxoSmithKline's antiviral drug Dovato showed efficacy comparable to Gilead Sciences' Biktarvy in studies. Dovato achieved a 89% virologic suppression rate at week 48, affecting market confidence in Gilead Sciences and leading to a decline in stock price.

2. On July 28, market analysts believe that Gilead Sciences' stock is not on the current recommended list of top five stocks, although its rating is a moderate buy, which weakened investor confidence and further pushed the stock price down.

3. On July 28, Gilead Sciences' HIV product sales grew by 6% in 2025, but the market still has doubts about its future growth potential, putting pressure on the stock price. The competition in the antiviral drug market is intensifying, and investors need to pay attention